BioMaxima Statistics

Total Valuation

BioMaxima has a market cap or net worth of PLN 49.27 million. The enterprise value is 64.12 million.

Market Cap	49.27M
Enterprise Value	64.12M

Important Dates

The last earnings date was Friday, November 28, 2025.

Earnings Date	Nov 28, 2025
Ex-Dividend Date	n/a

Share Statistics

BioMaxima has 4.19 million shares outstanding. The number of shares has decreased by -6.16% in one year.

Current Share Class	4.19M
Shares Outstanding	4.19M
Shares Change (YoY)	-6.16%
Shares Change (QoQ)	+3.57%
Owned by Insiders (%)	22.38%
Owned by Institutions (%)	n/a
Float	2.69M

Valuation Ratios

The trailing PE ratio is 78.33.

PE Ratio	78.33
Forward PE	n/a
PS Ratio	0.83
PB Ratio	1.05
P/TBV Ratio	1.07
P/FCF Ratio	214.21
P/OCF Ratio	24.50
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.05, with an EV/FCF ratio of 278.80.

EV / Earnings	98.80
EV / Sales	1.08
EV / EBITDA	13.05
EV / EBIT	47.89
EV / FCF	278.80

Financial Position

The company has a current ratio of 1.41, with a Debt / Equity ratio of 0.34.

Current Ratio	1.41
Quick Ratio	0.71
Debt / Equity	0.34
Debt / EBITDA	3.25
Debt / FCF	69.43
Interest Coverage	1.20

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	2.32%
Revenue Per Employee	469,143
Profits Per Employee	5,151
Employee Count	126
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	-152,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -7.54% in the last 52 weeks. The beta is 0.13, so BioMaxima's price volatility has been lower than the market average.

Beta (5Y)	0.13
52-Week Price Change	-7.54%
50-Day Moving Average	12.92
200-Day Moving Average	13.30
Relative Strength Index (RSI)	33.17
Average Volume (20 Days)	6,856

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, BioMaxima had revenue of PLN 59.11 million and earned 649,000 in profits. Earnings per share was 0.15.

Revenue	59.11M
Gross Profit	27.95M
Operating Income	1.34M
Pretax Income	497,000
Net Income	649,000
EBITDA	4.63M
EBIT	1.34M
Earnings Per Share (EPS)	0.15

Full Income Statement

Balance Sheet

The company has 1.12 million in cash and 15.97 million in debt, giving a net cash position of -14.86 million or -3.54 per share.

Cash & Cash Equivalents	1.12M
Total Debt	15.97M
Net Cash	-14.86M
Net Cash Per Share	-3.54
Equity (Book Value)	46.82M
Book Value Per Share	11.16
Working Capital	7.95M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.01 million and capital expenditures -1.78 million, giving a free cash flow of 230,000.

Operating Cash Flow	2.01M
Capital Expenditures	-1.78M
Free Cash Flow	230,000
FCF Per Share	0.05

Full Cash Flow Statement

Margins

Gross margin is 47.29%, with operating and profit margins of 2.27% and 1.10%.

Gross Margin	47.29%
Operating Margin	2.27%
Pretax Margin	0.84%
Profit Margin	1.10%
EBITDA Margin	7.84%
EBIT Margin	2.27%
FCF Margin	0.39%

Dividends & Yields

BioMaxima does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	6.16%
Shareholder Yield	6.16%
Earnings Yield	1.32%
FCF Yield	0.47%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BioMaxima has an Altman Z-Score of 2.64 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.64
Piotroski F-Score	4